Tag: clia 88

Why Theranos Is a Big Test for CMS and CLIA

By R. Lewis Dark, from the Volume XXIII, No. 8 – June 13, 2016 issue

OFFICIALS AT THE FEDERAL CENTERS FOR MEDICARE & MEDICAID SERVICES are at what may be the most important crossroads in the history of clinical laboratory regulation since Congress passed the CLIA 1988 legislation. Will CMS pursue the severe sanctions it disclosed to Theranos, Inc., and force the lab to close? Or will it soften its

View Article

National Lab Standards Coming For Patient Safety

By Robert Michel, from the Volume X No. 11 - August 18, 2003 issue

CEO SUMMARY: Because lab test data plays such an important role in medical decision-making, the Centers for Disease Control and Prevention (CDC) has launched a national effort to evaluate the quality of clinical and public health laboratories. In forming a Quality Institute, the goal is to issue a National Report on the Quality of Laboratory

View Article

Volume XXVI No. 2 – February 4, 2019

NOW THAT MOST HOSPITALS ARE INCLUDED as applicable laboratories that must report their PAMA private payer lab test price data to the Centers for Medicare and Medicaid Services, managers of those labs will benefit from the incisive analysis in this issue of the lessons learned during the 2017 PAMA reporting cycle. THE DARK REPORT further offers recommendations on how labs can do a better job of gathering and reporting their own data to CMS. Also, TDR delivers an exclusive analysis of why the Government Accounting Office's assertion that CMS will be paying billions more for Part B clinical lab tests is simply wrong.

See the full table of contents

Tag: clia 88

Enter Your Login Credentials